TCF25 Links Glucose Starvation to Lysosomal Cell Death

Nutrient deprivation forces cells to balance survival with the risk of damage caused by persistent metabolic stress. The Cell Reports study by Ren et al. examines this transition during glucose starvation and identifies transcription factor 25, or TCF25, as an important regulator of lysosomal function. Rather than treating autophagy as an isolated response, the work connects nutrient sensing, lysosomal acidification, ferritin turnover, and cell death in a single mechanistic framework.

Study Background and Research Question

Glucose supplies ATP and carbon skeletons for biosynthesis. When glucose becomes scarce, cells activate energy-conserving programs, including AMP-activated protein kinase signaling, while suppressing energy-intensive anabolic processes. Autophagy also increases, allowing lysosomes to recycle proteins and organelles into substrates that can support energy production.

This response is beneficial only within a defined stress window. Severe or sustained glucose deprivation can damage organelles and compromise cellular viability. Lysosomes are central to this boundary because they support autophagic recycling but can also become sources of injury when their membranes lose integrity. Lysosomal membrane permeability can therefore convert a compensatory response into lysosome-dependent cell death.

The central question was how cells coordinate these opposing outcomes. Specifically, the investigators asked whether an identifiable genetic regulator controls the shift from lysosome-mediated metabolic adaptation to lysosomal injury during prolonged glucose starvation.

Key Innovation from the Reference Study

The study’s main innovation is the identification of TCF25 as a nutrient sensor that operates through lysosomal acidification. A genome-wide CRISPR-Cas9 screen found that genes associated with lysosomal pathways were enriched among regulators of glucose-starvation-induced cell death. TCF25 was selected for detailed analysis because its loss altered the response to glucose deprivation.

Ren et al. propose a two-stage model. During early glucose starvation, TCF25 enhances V-ATPase-dependent acidification of lysosomes. This supports autophagic flux and ATP generation, helping cells maintain energy balance. During prolonged starvation, however, persistent TCF25 activity promotes ferritinophagy. The resulting lysosomal stress increases lysosomal membrane permeability and culminates in lysosome-dependent cell death.

This model is conceptually important because it explains how the same organelle can support survival and later contribute to cell death. It also places lysosomal proton-pumping activity upstream of a nutrient-stress decision rather than treating lysosomal damage as a purely downstream consequence.

Methods and Experimental Design Insights

The experimental strategy combines unbiased genetic screening, targeted mechanistic perturbation, cellular phenotyping, and an in vivo ischemia-reperfusion model. This layered design is useful for researchers because it moves from candidate discovery to pathway validation and then to physiological relevance.

• Genome-wide discovery: A CRISPR-Cas9 screen was used to identify genes that influence cell death under glucose starvation. The enrichment of lysosomal genes provided an unbiased entry point into the pathway.
• Candidate validation: TCF25-deficient cells were compared with control cells during glucose deprivation. The investigators also examined V-ATPase components, enabling a test of whether lysosomal acidification is functionally required rather than merely correlated with TCF25 activity.
• Metabolic and lysosomal readouts: The study assessed lysosomal acidification, autophagy-related activity, ATP generation, ferritinophagy, lysosomal membrane permeability, and cell viability. Examining these endpoints together helps distinguish adaptive recycling from terminal lysosomal damage.
• Genetic epistasis: Protection from starvation-induced death after disruption of TCF25 or V-ATPase components supports a pathway relationship between TCF25, lysosomal acidification, and cell death.
• In vivo translation: The investigators used a mouse hepatic ischemia-reperfusion injury model to test whether TCF25 deficiency changes tissue vulnerability under a clinically relevant metabolic and oxygen-stress condition.

Protocol Parameters

• Glucose-starvation design: Define early and prolonged deprivation phases separately, because the paper indicates that TCF25-mediated lysosomal activity is adaptive initially but damaging when sustained.
• Genetic controls: Include non-targeting controls, independent TCF25 guide RNAs, and, where feasible, rescue experiments to distinguish gene-specific effects from CRISPR-related artifacts.
• V-ATPase validation: Pair TCF25 perturbation with direct testing of V-ATPase pathway components and measure lysosomal acidification alongside viability.
• Ferritinophagy assessment: Interpret ferritin turnover together with lysosomal membrane integrity and cell-death measurements rather than using reduced ferritin abundance as a standalone indicator.
• In vivo interpretation: For ischemia-reperfusion studies, analyze both tissue injury and lysosomal pathway markers so that protection is connected to mechanism rather than inferred only from gross injury measurements.

Core Findings and Why They Matter

First, TCF25 was necessary for the full cell-death response to glucose starvation. Loss of TCF25 protected cells, indicating that the factor is not simply a passive marker of nutrient stress. The genetic-screen result and follow-up knockout experiments together identify TCF25 as a functional determinant of starvation sensitivity.

Second, TCF25 enhanced lysosomal acidification through the V-ATPase system. Acidification is essential for many lysosomal functions, including degradation of autophagic cargo. In the context of early glucose deprivation, this activity supported autophagy and ATP production, consistent with a role in metabolic adaptation.

Third, prolonged glucose starvation changed the consequence of this pathway. TCF25-mediated lysosomal activity constitutively activated ferritinophagy, increasing lysosomal stress and membrane permeability. The resulting phenotype was classified as lysosome-dependent cell death rather than a conventional apoptosis-centered response. This distinction matters experimentally: a negative result in a caspase-focused assay would not necessarily exclude the death mechanism described here.

Fourth, disruption of TCF25 or V-ATPase components prevented starvation-associated cell death. These findings strengthen the proposed causal chain: TCF25 activity influences V-ATPase-dependent acidification, which controls lysosomal processing and, under prolonged stress, contributes to membrane failure.

Finally, TCF25 deficiency protected mice from hepatic ischemia-reperfusion injury. This result extends the mechanism beyond cultured cells and suggests that nutrient depletion, altered oxygen availability, lysosomal dysfunction, and tissue injury may be connected through the TCF25 axis. The in vivo result is best viewed as evidence of physiological relevance, not as proof that TCF25 inhibition is ready for therapeutic use.

Comparison with Existing Internal Articles (if available)

The internal article Deferasirox for Iron and Lysosome Stress Assays is a useful workflow companion because it considers how iron availability can be experimentally perturbed while monitoring nutrient stress and lysosome-dependent death. Its practical emphasis differs from the reference study: Ren et al. establish TCF25–V-ATPase signaling genetically, whereas the internal resource discusses how an iron-directed perturbation might be incorporated into related assays.

The two resources should not be treated as interchangeable evidence. The Cell Reports paper directly supports the TCF25 mechanism and the hepatic ischemia-reperfusion phenotype. An iron-chelation workflow can test whether iron handling modifies that phenotype, but such an interaction remains a hypothesis unless demonstrated under matched genetic, nutritional, and lysosomal conditions.

Why this cross-domain matters, maturity, and limitations

The connection between lysosomal iron handling and metabolic-stress biology may interest researchers studying cancer treatment with iron chelators, ischemic injury, or other conditions in which nutrient availability is altered. However, the reference study is not a cancer study and does not establish inhibition of tumor growth, therapeutic iron depletion, or a specific clinical intervention. Its strongest contribution is mechanistic: it shows that ferritinophagy is positioned downstream of TCF25-regulated lysosomal acidification during prolonged glucose starvation.

Several transferability limits should guide follow-up work. Cell-type-specific dependence on TCF25 may vary with baseline lysosomal capacity, metabolic state, and iron storage. Glucose starvation is also a simplified stress model and does not reproduce the full complexity of ischemia, reperfusion, inflammation, or a tumor microenvironment. In addition, the study does not by itself determine whether lysosomal iron release, total cellular iron, or another ferritinophagy-associated event is the decisive trigger for membrane permeability.

Future experiments should therefore preserve the paper’s causal structure: perturb TCF25 or V-ATPase activity, verify changes in acidification, quantify ferritinophagy and membrane integrity, and then evaluate cell or tissue survival. This approach can distinguish pathway-specific effects from general cytotoxicity and clarify whether the adaptive-to-lethal transition is reversible.

Research Support Resources

Researchers can use Deferasirox (SKU A8639), an oral iron chelator, as an exploratory tool for iron-availability studies alongside glucose-starvation, ferritin, lysosomal acidification, and membrane-permeability readouts. The product information lists typical in vitro concentrations of 3–20 µM, but these are starting points rather than conditions validated by the TCF25 study; dose-response, vehicle, viability, and iron-specific controls are essential.

These experiments should not be interpreted as evidence for inhibition of tumor growth by deferasirox, iron uptake inhibition from transferrin, or apoptosis induction via caspase-3 activation in the Ren et al. model. Such endpoints require independent validation and should remain distinct from the paper’s demonstrated TCF25–V-ATPase–ferritinophagy mechanism.